<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Menden, Michael P</style></author><author><style face="normal" font="default" size="100%">Wang, Dennis</style></author><author><style face="normal" font="default" size="100%">Mason, Mike J</style></author><author><style face="normal" font="default" size="100%">Szalai, Bence</style></author><author><style face="normal" font="default" size="100%">Bulusu, Krishna C</style></author><author><style face="normal" font="default" size="100%">Guan, Yuanfang</style></author><author><style face="normal" font="default" size="100%">Yu, Thomas</style></author><author><style face="normal" font="default" size="100%">Kang, Jaewoo</style></author><author><style face="normal" font="default" size="100%">Jeon, Minji</style></author><author><style face="normal" font="default" size="100%">Wolfinger, Russ</style></author><author><style face="normal" font="default" size="100%">Nguyen, Tin</style></author><author><style face="normal" font="default" size="100%">Zaslavskiy, Mikhail</style></author><author><style face="normal" font="default" size="100%">Jang, In Sock</style></author><author><style face="normal" font="default" size="100%">Ghazoui, Zara</style></author><author><style face="normal" font="default" size="100%">Ahsen, Mehmet Eren</style></author><author><style face="normal" font="default" size="100%">Vogel, Robert</style></author><author><style face="normal" font="default" size="100%">Neto, Elias Chaibub</style></author><author><style face="normal" font="default" size="100%">Norman, Thea</style></author><author><style face="normal" font="default" size="100%">Tang, Eric K Y</style></author><author><style face="normal" font="default" size="100%">Garnett, Mathew J</style></author><author><style face="normal" font="default" size="100%">Veroli, Giovanni Y Di</style></author><author><style face="normal" font="default" size="100%">Fawell, Stephen</style></author><author><style face="normal" font="default" size="100%">Stolovitzky, Gustavo</style></author><author><style face="normal" font="default" size="100%">Guinney, Justin</style></author><author><style face="normal" font="default" size="100%">Dry, Jonathan R</style></author><author><style face="normal" font="default" size="100%">Saez-Rodriguez, Julio</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">AstraZeneca-Sanger Drug Combination DREAM Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Commun</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADAM17 Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Combined Chemotherapy Protocols</style></keyword><keyword><style  face="normal" font="default" size="100%">Benchmarking</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Datasets as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Antagonism</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Neoplasm</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Synergism</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphatidylinositol 3-Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphoinositide-3 Kinase Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 06 17</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">2674</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large drug combination dataset, consisting of 11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell lines, and results of a DREAM Challenge to evaluate computational strategies for predicting synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive methodological development and benchmarking. Winning methods incorporate prior knowledge of drug-target interactions. Synergy is predicted with an accuracy matching biological replicates for &gt;60% of combinations. However, 20% of drug combinations are poorly predicted by all methods. Genomic rationale for synergy predictions are identified, including ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31209238?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilkinson, Mark D</style></author><author><style face="normal" font="default" size="100%">Senger, Martin</style></author><author><style face="normal" font="default" size="100%">Kawas, Edward</style></author><author><style face="normal" font="default" size="100%">Bruskiewich, Richard</style></author><author><style face="normal" font="default" size="100%">Gouzy, Jerome</style></author><author><style face="normal" font="default" size="100%">Noirot, Celine</style></author><author><style face="normal" font="default" size="100%">Bardou, Philippe</style></author><author><style face="normal" font="default" size="100%">Ng, Ambrose</style></author><author><style face="normal" font="default" size="100%">Haase, Dirk</style></author><author><style face="normal" font="default" size="100%">Saiz, Enrique de Andres</style></author><author><style face="normal" font="default" size="100%">Wang, Dennis</style></author><author><style face="normal" font="default" size="100%">Gibbons, Frank</style></author><author><style face="normal" font="default" size="100%">Gordon, Paul M K</style></author><author><style face="normal" font="default" size="100%">Sensen, Christoph W</style></author><author><style face="normal" font="default" size="100%">Carrasco, Jose Manuel Rodriguez</style></author><author><style face="normal" font="default" size="100%">Fernández, José M</style></author><author><style face="normal" font="default" size="100%">Shen, Lixin</style></author><author><style face="normal" font="default" size="100%">Links, Matthew</style></author><author><style face="normal" font="default" size="100%">Ng, Michael</style></author><author><style face="normal" font="default" size="100%">Opushneva, Nina</style></author><author><style face="normal" font="default" size="100%">Neerincx, Pieter B T</style></author><author><style face="normal" font="default" size="100%">Leunissen, Jack A M</style></author><author><style face="normal" font="default" size="100%">Ernst, Rebecca</style></author><author><style face="normal" font="default" size="100%">Twigger, Simon</style></author><author><style face="normal" font="default" size="100%">Usadel, Bjorn</style></author><author><style face="normal" font="default" size="100%">Good, Benjamin</style></author><author><style face="normal" font="default" size="100%">Wong, Yan</style></author><author><style face="normal" font="default" size="100%">Stein, Lincoln</style></author><author><style face="normal" font="default" size="100%">Crosby, William</style></author><author><style face="normal" font="default" size="100%">Karlsson, Johan</style></author><author><style face="normal" font="default" size="100%">Royo, Romina</style></author><author><style face="normal" font="default" size="100%">Párraga, Iván</style></author><author><style face="normal" font="default" size="100%">Ramírez, Sergio</style></author><author><style face="normal" font="default" size="100%">Gelpi, Josep Lluis</style></author><author><style face="normal" font="default" size="100%">Trelles, Oswaldo</style></author><author><style face="normal" font="default" size="100%">Pisano, David G</style></author><author><style face="normal" font="default" size="100%">Jimenez, Natalia</style></author><author><style face="normal" font="default" size="100%">Kerhornou, Arnaud</style></author><author><style face="normal" font="default" size="100%">Rosset, Roman</style></author><author><style face="normal" font="default" size="100%">Zamacola, Leire</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, Jaime</style></author><author><style face="normal" font="default" size="100%">Carazo, Jose María</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Guigó, Roderic</style></author><author><style face="normal" font="default" size="100%">Navarro, Arcadi</style></author><author><style face="normal" font="default" size="100%">Orozco, Modesto</style></author><author><style face="normal" font="default" size="100%">Valencia, Alfonso</style></author><author><style face="normal" font="default" size="100%">Claros, M Gonzalo</style></author><author><style face="normal" font="default" size="100%">Pérez, Antonio J</style></author><author><style face="normal" font="default" size="100%">Aldana, Jose</style></author><author><style face="normal" font="default" size="100%">Rojano, M  Mar</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santa Cruz, Raul</style></author><author><style face="normal" font="default" size="100%">Navas, Ismael</style></author><author><style face="normal" font="default" size="100%">Schiltz, Gary</style></author><author><style face="normal" font="default" size="100%">Farmer, Andrew</style></author><author><style face="normal" font="default" size="100%">Gessler, Damian</style></author><author><style face="normal" font="default" size="100%">Schoof, Heiko</style></author><author><style face="normal" font="default" size="100%">Groscurth, Andreas</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">BioMoby Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Interoperability with Moby 1.0--it's better than sharing your toothbrush!</style></title><secondary-title><style face="normal" font="default" size="100%">Brief Bioinform</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brief Bioinform</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Database Management Systems</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Information Storage and Retrieval</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Programming Languages</style></keyword><keyword><style  face="normal" font="default" size="100%">Systems Integration</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">220-31</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The BioMoby project was initiated in 2001 from within the model organism database community. It aimed to standardize methodologies to facilitate information exchange and access to analytical resources, using a consensus driven approach. Six years later, the BioMoby development community is pleased to announce the release of the 1.0 version of the interoperability framework, registry Application Programming Interface and supporting Perl and Java code-bases. Together, these provide interoperable access to over 1400 bioinformatics resources worldwide through the BioMoby platform, and this number continues to grow. Here we highlight and discuss the features of BioMoby that make it distinct from other Semantic Web Service and interoperability initiatives, and that have been instrumental to its deployment and use by a wide community of bioinformatics service providers. The standard, client software, and supporting code libraries are all freely available at http://www.biomoby.org/.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/18238804?dopt=Abstract</style></custom1></record></records></xml>